Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

[1]  A. Polyzos.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  J. Hajdenberg,et al.  The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment , 2007 .

[3]  A. Hauschild,et al.  EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial , 2007 .

[4]  R. Motzer,et al.  Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) , 2007 .

[5]  H. Pitot,et al.  Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results , 2007 .

[6]  M. Michaelson,et al.  Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers , 2007 .

[7]  A. Ravaud,et al.  Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients , 2007 .

[8]  A. Berkenblit,et al.  Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) , 2007 .

[9]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[10]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[11]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[12]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[14]  M. Gore,et al.  Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Aitchison,et al.  Treatment for renal cancer: are we beyond the cytokine era? , 2006, Nature Clinical Practice Urology.

[16]  J. Hainsworth,et al.  Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Figlin,et al.  Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Kohn,et al.  Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[20]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  O. Rouvière,et al.  Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? , 2006, Nature Clinical Practice Oncology.

[23]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[24]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[26]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Ravaud,et al.  Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial , 2005 .

[28]  D. Grignon,et al.  Clear cell renal cell carcinoma. , 2005, Clinics in laboratory medicine.

[29]  E. Small,et al.  Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Robert N. Hughes,et al.  Cancer: Principles and Practice of Oncology , 2005 .

[31]  J. Yang.  Bevacizumab for Patients with Metastatic Renal Cancer , 2004, Clinical Cancer Research.

[32]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[33]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[35]  V. Sukhatme,et al.  Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.

[36]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[37]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[39]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[40]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[41]  R. Burk,et al.  The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis , 2000, Oncogene.

[42]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  P. Schirmacher,et al.  Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors , 1999, Journal of Molecular Medicine.

[44]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[45]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[46]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.